Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
|Articles|October 1, 2021
Merck Acquires Acceleron for $11.5 Billion
Author(s)BioPharm International Editors
Merck’s 11.5 billion acquisition of Acceleron gives them access to their lead therapeutic candidate, sotatercept.
Advertisement
Merck, known as MSD outside of the United States and Canada, announced on Sept. 30, 2021, that it had agreed to acquire Acceleron, a biopharmaceutical company, for approximately $11.5 billion. Acceleron is focused on the transforming growth factor (TGF)-beta superfamily of proteins, which play a key role in the regulation of cell growth, differentiation, and repair.
Acceleron’s lead therapeutic candidate is sotatercept, which has a novel mechanism of action with the potential to help patients with pulmonary arterial hypertension (PAH), a progressive and life-threatening blood disorder. It is currently in Phase III trials as an add-on to the current standard of care for PAH treatment.
Accleron’s portfolio also includes Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation fusion protein approved in the US, Europe, Canada, and Australia for the treatment of anemia in certain rare blood disorders. Reblozyl has been developed and commercialized in a collaboration with Bristol Myers Squibb.
“Strategic business development is a top priority for Merck as we look to drive sustainable growth and further bolster and balance our pipeline with breakthrough science,” said Rob Davis, CEO and president, Merck, in an Acceleron press release. “Acceleron’s innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s proud legacy in cardiovascular disease.”
“This agreement with Merck represents the culmination of decades of work by Acceleron researchers successfully leveraging our company’s deep scientific expertise in the biology of the TGF-beta superfamily and driven by an unwavering dedication to delivering life-changing medicines for patients,” said Habib Dable, CEO and president, Acceleron, in the press release. “We believe Merck is well-positioned to apply its industry-leading clinical and commercial capabilities to harness the potential of sotatercept as we join together to help make an impact on cardiopulmonary disease for the benefit of patients.”
Source:
Advertisement
Related to this article
Biocon's Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, has become the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA's newly adopted tailored clinical approach, which can reduce comparative efficacy trial requirements.
Telix will acquire ITM for $1.65 billion, gaining a phase 3-validated therapy that cut GEP-NET progression risk versus everolimus.
mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
Dualitas will screen over 300,000 bispecific combinations for Roche, backing a deal worth up to $1 billion in immunology research.
GSK's new trispecific TCE targets 2 tumor antigens plus T cells, aiming to improve on the tolerability of current myeloma therapies.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Advertisement
Advertisement